pharmaphorum
OCTOBER 27, 2020
US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Merimepodib is the subsidiary’s primary asset, and the biotech now says it is to offers to acquire or license the drug.
Pharmaceutical Technology
APRIL 27, 2023
GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 There are currently 885 clinical trials ongoing or completed for prophylactic mRNA vaccines for infectious diseases and double the number of Phase I trials in 2022 compared to 2021. billion by 2028.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 17, 2024
Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding 5.
Drug Discovery World
OCTOBER 6, 2022
In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. Identifying the population subsets who will benefit is essential to the success of these therapies in both the clinic and in the clinical trials that will bring these drugs to market. .
Drug Discovery World
MARCH 7, 2023
In 2023, the company revealed data from a Phase III trial which showed that its vaccine candidate DCVax-L more than doubled overall survival in glioblastoma patients. She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials.
Expert insights. Personalized for you.
97 
Let's personalize your content